1. Introduction
Cancer-related hypercalcemia is seen in up to 30% of patients with malignancies [ 1 ]. Very often, this is accompanied by increased bone resorption [ 2 ]. Calcium plays a vital role in many different physiological functions, for example in the contraction of all muscle cell types and neuronal signalling. In healthy individuals, the plasma concentration of calcium is tightly regulated by the interplay of parathyroid hormone (PTH), vitamin D and calcitonin [ 2 ]. In patients with malignant disorders, calcium balance is often disrupted, reflected by elevated calcium plasma levels [ 1 ]. Calcium is partly bound to albumin and its plasma levels are either expressed as albumin corrected levels (common in clinical practice) or as total Ca 2+ levels (free + bound). Hypercalcemia is defined in patients as mild for levels between 10.5 and 11.9 mg/dL (2.6–2.9 mmol/L), as moderate between 12 and 13.9 mg/dL (3.0–3.4 mmol/L), and as severe above 14 mg/dL (3.5 mmol/L) serum total Ca 2+ [ 1 , 3 ]. The main cause of malignancy-related hypercalcemia is an imbalance in bone formation and resorption [ 3 ].
The most prevalent clinical symptoms with hypercalcemia relate to neurologic, psychiatric, gastrointestinal, cardiovascular and renal abnormalities [ 2 , 3 , 4 ]. Neurologic and psychiatric symptoms include fatigue, lethargy, musculoskeletal pain, depression, and even coma. Reduced motility of the gastrointestinal tract can cause constipation and reduced appetite. Cardiovascular symptoms include cardiac arrhythmias and hypertension. Moreover, renal failure is frequently present in hypercalcemia. Symptoms of hypercalcemia are frequently seen in cancer patients. For example, in multiple myeloma patients, serum calcium levels were an independent predictor of quality of life, fatigue and physical functioning [ 5 ].
There are three proposed mechanisms by which malignancies can affect the balance between Ca incorporation in bone and its resorption [ 2 ]. The first is associated with increased degradation of bone by osteoclasts, which become activated by factors secreted by metastases or primary tumours in or close to the bone. A second mechanism involves increased levels of inflammatory mediators like interleukin 6 (IL-6), prostaglandin E2 (PGE-2), and of PTH-related protein (PTHrP), which directly cause increased breakdown of bone. A third possibility is based on the connection to coexisting primary hyperparathyroidism. Of these three proposed mechanisms, the one involving PTHrP secreted by the tumour is considered the most prominent and responsible for 80% of all malignancy-related hypercalcemia patients [ 4 ].
PTHrP is a protein between 139 and 173 amino acids in size. Its N-terminal shows homology with PTH. PTHrP is produced in low concentrations by practically all tissues. PTHrP produced by the tumour can bind and activate the PTH receptor leading to increased bone demineralization and increased renal reabsorption of calcium [ 6 ]. Both these processes contribute to the increase in plasma calcium levels. Bone resorption can lead to TGFβ release, which in turn stimulates PTHrP secretion by tumour cells, thus initiating a vicious cycle [ 6 , 7 ]. The elevation of PTHrP in C26 adenocarcinoma cells has been reported to depend on an increase in cyclooxygenase 2 (COX-2) activity, which in parallel also results in an elevated PGE-2 production [ 8 ]. Apart from its effects on bone calcium turnover, PTHrP also directly stimulates muscle wasting and adipose tissue browning [ 9 ]. Possibly related to this, serum PTHrP levels were found to be predictive of weight loss in cancer patients independently of hypercalcemia, inflammation and tumour burden [ 10 ]. Together, these findings suggest an overlap between features of cancer cachexia and malignancy-related hypercalcemia, two clinically relevant paraneoplastic syndromes. In order to investigate whether this overlap would also apply to possible intervention strategies for cachexia, the present study was initiated. This study investigated the effects of a diet enriched in leucine, protein and fish oil on PTHrP related changes of plasma Ca levels in a tumour-induced cachexia model. In the same animals, we previously showed significant improvement of cachexia-related outcomes in those mice that had received such specific nutritional combination (SNC) [ 11 ]. Starting from the hypothesis that supplementation of fish oil and leucine might also reduce plasma Ca 2+ levels in tumour-bearing animals, we further investigated the involvement of PTHrP and COX-2 in the regulation of Ca 2+ levels by docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), respectively. To this end, we performed a series of in vitro experiments with C26 cells.
2. Results
2.1. Effect of Leucine and Fish Oil in Vivo in Experiment A,B
2.1.1. Calcium Levels and Their Correlation with Carcass Mass, Organ Masses and EDL Muscle Function.
We determined whether cachexia-associated outcomes might be related to plasma Ca 2+ levels. As previously published, carcass mass was decreased, as seen in Figure 1 A,C, in tumour-bearing (TB) mice, compared to the carcass mass of control mice which was improved to a certain extent by supplementation of fish oil and leucine or the SNC [ 11 ]. Our additional analysis showed a two-fold increase in plasma Ca 2+ levels in the tumour-bearing animals as seen in Figure 1 . The combination of leucine and fish oil was able to significantly reduce the tumour-induced hypercalcemia, whereas the individual components could not reduce hypercalcemia as seen in Experiment A, Figure 1 B. Similar reductions in plasma Ca 2+ levels were found in animals supplemented with the complete SNC containing high protein, leucine, fish oil and oligosaccharides as seen in Experiment B, Figure 1 D. Moreover, plasma Ca 2+ levels were negatively correlated with carcass weight and with multiple organ masses as seen in Figure 1 E and Table 1 . Muscle function of mEDL was determined ex vivo in an organ bath. For all frequencies at which tetanus could be obtained (>83 Hz), muscle function parameters (maximal force, maximal contraction velocity and maximal relaxation velocity), correlated negatively with calcium levels (R below −0.7 and p < 0.05) as seen in Table 2 . When the muscle function parameters, maximal force, maximal contraction velocity and maximal relaxation velocity were corrected for muscle mass, negative correlations remained, though R values were less (between −0.35 and −0.7), and significant levels were obtained for all parameters for frequencies ≥100 Hz.
2.1.2. Plasma PGE-2 and Tumour PTHrP
Inflammatory mediators like PGE-2 and PTHrP have been reported to play a potential role in the onset of hypercalcemia. Plasma PGE-2 levels were significantly increased in TB compared to control mice as seen in Figure 2 B. This increase was reduced upon supplementation of fish oil either with or without added leucine. Plasma Ca 2+ and PGE-2 levels correlated significantly (Pearson r = 0.6062 with p < 0.0001) as seen in Figure 2 F. Tumour PTHrP levels were significantly lower in TB animals that had received diets enriched with fish oil and leucine compared to TB animals without supplementation as seen in Figure 2 C. Tumour PTHrP levels did not correlate with plasma Ca 2+ levels. However, it should be noted that there were no PTHrP levels determined in control animals since they have no tumour.
2.2. Effect of Leucine and Fish Oil in Vitro in Experiment C–E
2.2.1. Supplementation of C26 Cells with Nutritional Components used in Vivo in Experiment C,D
To determine possible mechanisms behind the effects of the nutritional supplementation with leucine and fish oil in C26 mice, a sequence of in vitro experiments was performed. In Experiment C, small numbers of C26 cells were incubated with omega-3 fatty acids EPA or DHA, or leucine added to the medium and PTHrP production was measured. Experiments showed that DHA and EPA at a concentration of 50 μM (DHA), 100 μM (DHA) and 100 μM (EPA) significantly reduced C26 PTHrP production by 36%, 39% and 35%, respectively, as seen in Figure 3 A,B. Leucine had no effect on PTHrP production in vitro as seen in Figure 3 C. None of the components had any effect on viability or toxicity in the concentrations tested as seen in Figure S1 . Given that DHA and EPA were found to be the most potent in reducing PTHrP, these were incorporated into the next experiments. To test the consistency of the findings and to mimic the effects of the potent components DHA and EPA on the tumour, we tested the effects on cells with a higher confluence in Experiment D. The effect of EPA was no longer present. The effect of DHA, however, was reproducible in these confluent cells with reductions of 32% and 34% at 50 μM DHA and 100 μM DHA, respectively, as seen in Figure 3 D,E.
2.2.2. Possible Involvement of COX-2 in the Effect of Fish Oil in Experiment E
DHA is known to reduce COX-2 activity [ 12 ], and PTHrP production is known to be stimulated upon stimulation of COX-2 [ 8 ]. Therefore, to further elucidate the possible mode of action of DHA, we determined whether COX-2 was involved in the PTHrP reducing effects of DHA in Experiment E. This was done by measuring PGE-2 production upon incubation of C26 cells with DHA. As a positive control, the specific COX-2 inhibitor celecoxib (CXB) was used. Results showed that DHA was not able to reduce PGE-2 production in C26 cells where CXB reduced PGE-2 levels with 73% at a dose of 0.01 μM, as seen in Figure 4 A,B. Moreover, PTHrP production of C26 cells was not reduced when COX-2 activity was inhibited by incubation with CXB as seen in Figure 4 C. This indicates that the effect of DHA was possibly not mediated via the enzyme COX-2. In Experiment D,E, none of the conditions resulted in an increased toxicity, as measured by LDH as seen in Figure S2 .
3. Materials and Methods
3.1. In Vivo Experiments
3.1.1. Animals and Experimental Diets
For the present study, we started our research by analysing archived materials from a previous in vivo study, which made it possible to limit new animal research. That study investigated the effects of a specific nutritional combination of oligosaccharides, high protein, leucine, and fish oil on muscle and daily activity [ 11 ]. Experimental procedures have been described in detail in the previous paper. Briefly, male CD2F1 mice aged 6–7 weeks were divided into weight-matched groups: (1) control mice receiving control diet high in protein (C), (2) tumour-bearing mice receiving the same control diet (TB), and (3) tumour-bearing mice receiving experimental diets. In Experiment A, the effect of additional leucine (LEU) and fish oil (FO) on top of the high protein diet was tested. In Experiment B, the specific nutritional combination (SNC) of oligosaccharides, high protein, leucine and fish oil was used. All diets used in the different experiments were iso-caloric, by exchanging additional protein or fat with carbohydrates. In Experiment A, AIN93-M, supplied as pellets, was used as control diet, and for the experimental groups the specific nutritional components were added. In Experiment B, a more human-like control diet was used which was iso-caloric and isonitrogenous to the diet used in Experiment A. Both the control diet as the iso-caloric experimental SNC in Experiment B were supplied as dough. Experimental procedures were approved by the Animal Ethics Committee (DEC consult, Bilthoven, The Netherlands) and complied with the principles of good laboratory animal care (DEC/DAN100).
3.1.2. Experimental Protocol
Murine C26 adenocarcinoma cells were cultured and inoculated as reported previously [ 11 , 13 ]. Briefly, under general anaesthesia (isoflurane/N 2 O/O 2 ), tumour cells (5 × 10 5 cells in 0.2 mL) were inoculated subcutaneously into the right inguinal flank of the mice. Control (C) animals received a sham injection with 0.2 mL HBSS. Animals were weighed and anaesthetized (isoflurane/N 2 O/O 2 ) at day 20 after tumour inoculation. Skeletal muscle and internal organs were dissected and weighed. Carcass mass was calculated by subtracting tumour mass from body mass. Ex vivo EDL muscle function was measured at different frequencies ranging from 20 to 167 Hz. Tetanus was reached at frequencies ≥83 Hz.
3.1.3. Plasma PGE-2 and Tumour PTHrP in Experiment A
In animals from Experiment A, plasma PGE-2 was measured using a commercial anti-PGE-2 rabbit polyclonal antibody-based direct enzyme immunoassay (Oxford Biomedical Research, Oxford, MI, USA) according to the manufacturer’s protocol. PTHrP levels in the tumour of animals in Experiment A were measured using a quantitative PTHrP enzyme-linked immunosorbent (ELISA) assay kit (USCN Life Science Inc., Wuhan, Hubei, China) according to the manufacturer’s protocol. PTHrP levels were expressed as amount per milligram of protein as determined using a Pierce TM BCA protein kit (Thermo Fisher Scientific, Rockford, Illinois, USA). Unfortunately, the amount of stored plasma material was insufficient to determine plasma PTHrP levels.
3.1.4. Plasma Calcium in Experiment A,B
To investigate if the elevation of calcium levels was linked to body and organ masses and PGE-2 levels, total plasma Ca 2+ levels (free calcium + calcium bound to albumin) were determined calorimetrically at the Clinical Chemistry Laboratory Hospital Reinier de Graaf (Delft, the Netherlands).
3.2. In Vitro Experiments
To determine possible underlying mechanisms, we set up a series of in vitro experiments. First, we tested the main components present in the diets used in the mouse studies on a low number of tumour cells, as seen in Experiment C. As a control, viability and toxicity assays were performed to rule out potentially toxic effects of components in the concentrations tested. Subsequently, we continued with the most potent compounds on a larger number of cells, as seen in Experiment D, to test their potency in situations more resembling the in vivo situation (i.e., the tumour consists of a very large number of cells). Lastly, we examined a possible mechanism of action of the most potent compound, as seen in Experiment E, by assessing the possible involvement of COX-2 by using a specific COX-2 inhibitor. In Experiment D,E, only toxicity assays were performed.
3.2.1. Culture of Murine C26 Cells
All in vitro experiments were performed using murine C26 tumour cells (American Type Culture Collection; ATCC, Teddington, UK). Cells were cultured in DMEM with 10% heat-inactivated foetal bovine serum at 37 °C in a 5% CO 2 humidified air atmosphere. For supplementation in Experiment C,D,E, cells were seeded in a 24-wells plate. For Experiment C, 25,000 cells were seeded leading to a confluence of 10–20% after 24h with ample cell–cell contact. For Experiment D,E, 250,000 cells were seeded leading to a confluence of 80–90% after 24h with a high degree of cell–cell contact.
3.2.2. PTHrP and PGE-2 Production upon Supplementation of C26 cells with DHA, EPA, Leucine and CXB
After 24 h of incubation, culture medium from each well was removed and C26 cells were supplemented with test compound or vehicle control. Supplementation for 24h was performed with different concentrations of either docosahexaenoic acid (DHA, 22:6 n-3 ; Sigma-Aldrich, Sigma-Aldrich Chemie GmbH, Schnelldorf, Germany), eicosapentaenoic acid (EPA, 20:5 n-3 ; Sigma-Aldrich Chemie GmbH), leucine (Sigma-Aldrich Chemie GmbH), or celecoxib (CXB, Sigma-Aldrich Chemie GmbH). Ethanol was used as solvent for ω-3 PUFAs (DHA and EPA), DMSO was used as solvent for CXB and leucine was dissolved in PBS. In all cases, final ethanol/DMSO concentration never exceeded 0.1% v/v. All experiments were performed at least three times, and each condition was done in duplicate or triplicate. After 24h of supplementation, supernatant was removed for analysis of PTHrP and PGE-2. PTHrP production in C26 cell supernatant was measured using a commercially available ELISA (USCN Life Science Inc., Wuhan, Hubei, China) according to the manufacturer’s protocol. PGE-2 production was measured using a commercially available monoclonal ELISA kit (Cayman chemical, Ann Arbor, Michigan, USA).
3.2.3. Viability and Cytotoxicity
For Experiment C, cell viability was measured with the Cell Proliferation (XTT) Kit II (Roche, Basel, Switzerland), according to the manufacturer’s protocol. Cells seeded in a 24-wells plate were incubated for 30 to 90 min with the XTT reagent mix. After incubation, 100 uL supernatant was transferred to a 96-wells plate and absorbance was measured at 450 nm using an ELISA plate reader. As a negative control, cells were treated with Triton X100 which resulted in total cell lysis.
Cytotoxicity was measured for each experiment with the Cytotoxicity Detection (LDH) Kit (Roche, Basel, Switzerland), according to the manufacturer’s protocol. This kit measures the relative LDH content present in the supernatant, which reflects cytotoxicity. Supernatant of the cells seeded in a 24-wells plate was transferred to a 96-wells plate and used to measure LDH content. Absorbance was measured at 492 nm using an ELISA plate reader. As a positive control, cells were incubated with Triton X100 which results in total cell lysis. Viability and cytotoxicity results are reported in Figures S1 and S2 .
3.3. Statistics
All data are expressed as mean ± SEM. Statistical analyses were performed using GraphPad Prism 5 (GraphPad Software Inc., La Jolla, California, USA). In Experiment A, different batches of animals were used. Therefore, for all parameters, it was defined that combining the data was allowed, meaning no interaction between groups and experiments was present. For all the in vivo experiments, comparisons were made using an analysis of variance (ANOVA) with a Dunnett’s multiple comparison test with the tumour-bearing group without nutritional supplementation as reference. Differences were considered significant at a p -value < 0.05. Correlations were calculated and Pearson correlation coefficients with a p -value < 0.05 were considered significant. For the in vitro experiments, comparisons were made using an ANOVA with a Dunnett’s multiple comparison test with the vehicle control as reference. Differences were considered significant at a p -value < 0.05.
4. Discussion
In line with our hypothesis and the available literature [ 14 , 15 ], tumour-bearing cachectic mice showed hypercalcemia. Our data also demonstrate that plasma Ca 2+ levels correlated negatively with carcass mass and several organ masses. In addition, Ca 2+ levels positively correlated with plasma PGE-2 levels. Moreover, the nutritional combination reduced elevated plasma PGE-2 levels and PTHrP levels in tumour tissue.
Only a few studies on the relation between fish oil, or its main components EPA and DHA, and tumour-associated hypercalcemia have been reported in the literature. In a 1984 study, mice bearing the prostaglandin producing HSDM1 fibrosarcoma, received menhaden fish oil high in EPA (EPA:DHA ratio of 2.4:1). This intervention caused a reduction of plasma Ca 2+ levels in tumour-bearing mice [ 16 ]. Since hypercalcemia is related to bone mineral density and a reduction of bone mineral density is a well-known feature of the C26 model, we also investigated the literature on reported associations between fish oil treatment and bone mineral density. However, a systematic review on ω3 fatty acids and osteoporosis concluded that clear conclusions are difficult to make, due to the small number of studies and modest sample sizes [ 17 ]. In breast cancer survivors, high doses of EPA and DHA were reported to reduce bone resorption [ 18 ]. Moreover, fish oil was found to prevent breast cancer cell metastasis to bone and osteolytic lesions in a human mouse xenograft model [ 19 ].
In our study, decreased Ca 2+ levels were only observed when leucine and fish oil were combined. Interestingly, this suggests that leucine might have an additional favourable effect, but only in the presence of fish oil. Leucine has been reported to influence insulin sensitivity of tissues and to increase insulin release [ 20 ]. In addition, insulin seems to have an anti-phosphaturic effect [ 21 ]. It was reported that in vivo administration of PTH induced a decline in tubular reabsorption of phosphate, which was reversed by superimposition of an euglycemic hyperinsulinemia within the physiologic range [ 21 ]. The effect of leucine on hypercalcemia might, therefore, be explained by increased insulin release, leading to increased renal absorption of phosphate.
In our study, dietary fish oil alone, or combined with leucine, reduced plasma PGE-2 levels. Omega-3 PUFAs have been evaluated in various clinical studies for their immunomodulatory capacity [ 22 ]. Already after a week of intervention with a medical food high in protein, leucine, fish oil, and specific oligosaccharides, plasma PGE-2 levels decreased in cancer patients receiving radiotherapy [ 23 ]. The SNC tested in our study has also been shown to exert immunomodulatory effects by reducing IL-6, TNF-α, IL-4, and PGE-2 plasma levels in the C26 model [ 24 ]. Another study reported a decrease in PGE-2 levels in a small intestinal tumour of Apc Min/+ mice upon feeding with a high fat diet rich in fish oil [ 25 ]. Eicosapentaenoic acid has been reported to decrease the pro-inflammatory steady state by reducing the levels of TNF-α, IL-1β, IL-6, and IL-8 in serum or plasma [ 26 ]. Moreover, EPA induces a shift in the pattern of prostaglandins produced by COX-2, from PGE-2 production with arachidonic acid (AA) as substrate, to relatively more PGE-3 produced with EPA as substrate [ 27 , 28 ]. These results are all in line with our findings. However, there is also some conflicting evidence showing that both DHA and EPA can stimulate PGE-2 production in both ScGT1 neuronal cells, raw 264.7 murine macrophages and human primary monocyte-derived macrophages [ 29 , 30 ].
The negative correlations between carcass weight and calcium levels, and those between muscle weight and calcium indicate that the cachexia and hypercalcemia might be linked in our model. It is, however, difficult to indicate to what extent they are related. With regards to muscle function, it is, however, possible to correct for muscle mass. We revealed a high inverse correlation between muscle function and hypercalcemia for maximal force, contraction velocity and relaxation velocity. This correlation remained after correction for muscle mass, though with lower R values, indicating that there seems to be a mass-independent compound in the relationship between calcium levels and loss of muscle function as part of the cachexia syndrome.
Previous studies report that hypercalcemia in the C26 model is mediated by IL-6 and PTHrP [ 31 ]. We realize the limitations of this study as we were unable to measure either PTHrP or IL-6 in plasma. From literature, we know that the same SNC is able to reduce IL-6 plasma levels in the C26 model [ 24 ]. Moreover, our results showed that the nutritional combination of fish oil and leucine reduced PTHrP levels in the tumour. Elevation of PTHrP in malignancy is thought to be mediated by an increase in COX-2 activity [ 8 ]. Therefore, the strong positive correlations of Ca 2+ levels with PGE-2, a major COX-2-mediated inflammatory mediator, might suggest that PTHrP is also involved in the induction of hypercalcemia. To test this hypothesis, we performed a sequence of in vitro experiments.
Our results showed that among the nutrients tested in vivo, EPA and DHA seemed most potent when a low number of cells was used, as seen in Experiment C. Interestingly, leucine did not have any effect in vitro, whereas in vivo a combination of fish oil and leucine was needed to reduce Ca 2+ and tumour PTHrP. This might be explained by acknowledging a synergistic effect of leucine when combined with EPA/DHA compared to being administered alone on the reduction of Ca 2+ and tumour PTHrP. To test the potency in situations more similar to the in vivo situation, where C26 cells grow in a solid tumour in the flank of the mice, we incubated a larger number of cells with DHA or EPA, as seen in Experiment D. It should be mentioned that in vivo, the tumour consists of not only C26 cells but also stromal and inflammatory cells, which were not included in our in vitro studies. At this higher confluency, where more cell–cell contact was present, only DHA proved able to reduce PTHrP production. Previous research shows that ω3 PUFAs may exert anti-cancer activities on several different cancer types [ 32 ]. Moreover, ω3 PUFAs have been found to be pro-apoptotic and anti-proliferative in human colorectal cancer cell lines [ 33 ]. However, in our study, the effects on PTHrP production were independent of cytotoxicity or viability. One could also argue that it is unlikely that the proliferation of the cells changed, because XTT remained the same. PTHrP production in C26 cells has previously been related to COX-2 activity [ 8 ], and DHA is known to be able to inhibit COX-2 activity [ 12 ]. Therefore, our next step was to determine possible mediators of PTHrP by testing involvement of COX-2, as seen in Experiment E. To this end, we incubated a large number of cells with a specific COX-2 inhibitor CXB, and measured the effect of DHA on PGE-2 production and the effect of CXB on PTHrP and PGE-2 production. Surprisingly, DHA was not able to reduce PGE-2 production, whereas CXB was. Moreover, PTHrP production did not change upon supplementation with CXB. This was an unexpected result, since a different COX-2 inhibitor (NS-398) was able to reduce PTHrP production in C26 cells [ 8 ]. A possible explanation for the difference between our finding and the literature is that in the NS-398 experiments, PTHrP production was only present in a spheroid culture and not in monolayer cultures; in our experiments, PTHrP production was already visible in a monolayer culture. From our in vitro experiments, we can conclude that DHA is possibly the most potent component in reducing the PTHrP levels. The reduction in PTHrP production was most likely not mediated by COX-2, leaving the mechanism of action of DHA still an open question.
Bone health and calcium homeostasis are important factors affected by malignancy. In this study, we showed that tumour-induced hypercalcemia is highly correlated with several cachexia related outcomes. We also showed that a nutritional intervention high in leucine and fish oil can reduce the detrimental effects of the tumour on calcium homeostasis in a tumour-bearing C26 mouse model. This is clinically relevant, since calcium homeostasis can have a large impact on the daily life of patients. In a study of 686 multiple myeloma patients, serum calcium levels were associated with quality of life (QOL) scores, appetite loss, nausea/vomiting, physical functioning ( p < 0.001), cognitive functioning ( p = 0.001), and the scores for fatigue and pain ( p < 0.001) [ 5 ]. Moreover, we elucidated possible mechanisms behind the beneficial effects of fish oil supplementation on hypercalcemia. The ω3 PUFA DHA, one of the potent components found in vivo, reduced PTHrP production of C26 cells in vitro. A reduction in PTHrP is important, independent of its effects on calcium homeostasis and bone health, since PTHrP is also related to an increase in adipose tissue browning and muscle wasting [ 9 , 34 ]. Further research in the mechanism involved in the beneficial effects of ω3 PUFA is needed to further optimize nutritional support for cancer patients.
Acknowledgments
We would like to thank Judith Hulsman, Jvalini Dwarkasing and Merel van Rooijen for performing part of the in vitro experiments and Diane Kegler for the animal activities and the support of the Animal Care Facility (CKP) of the University of Wageningen.
Supplementary Materials
Click here for additional data file.
The following are available online at https://www.mdpi.com/1422-0067/20/20/4978/s1 .
Author Contributions
R.L.C.P., M.P. and K.v.N. are main contributors to the in vitro work. K.v.N., J.F., M.v.D. and A.v.H. are main contributors to the in vivo work. R.L.C.P. and K.v.N. were leading writers. All authors contributed to discussions, set up and writing of the paper.
Funding
The research was funded by both Nutricia Research and the Wageningen University.
Conflicts of Interest
Authors from the universities: The authors declare no conflicts of interest. Authors Danone Nutricia Research: Danone Nutricia Research is a medical nutrition company.
Abbreviations
References
1. Stewart A.F. Hypercalcemia Associated with Cancer New Engl. J. Med. 2005 352 373 379 10.1056/NEJMcp042806 15673803
2. Guise T.A. Mundy G.R. Cancer and Bone Endocr. Rev. 2013 19 18 54 10.1210/edrv.19.1.0323 9494779
3. Goldner W. Cancer-Related Hypercalcemia J. Oncol. Pract. 2016 12 426 432 10.1200/JOP.2016.011155 27170690
4. Mirrakhimov A.E. Hypercalcemia of malignancy: An update on pathogenesis and management N. Am. J. Med. Sci. 2015 7 483 493 10.4103/1947-2714.170600 26713296 PMC4683803
5. Wisløff F. Kvam A.K. Hjorth M. Lenhoff S. Serum calcium is an independent predictor of quality of life in multiple myeloma Eur. J. Haematol. 2007 78 29 34 10.1111/j.0902-4441.2006.t01-1-EJH2887.x 17038019
6. Mundy G.R. Edwards J.R. PTH-related peptide (PTHrP) in hypercalcemia J. Am. Soc. Nephrol. 2008 19 672 675 10.1681/ASN.2007090981 18256357
7. Yin J.J. Selander K. Chirgwin J.M. Dallas M. Grubbs B.G. Wieser R. Massagué J. Mundy G.R. Guise T.A. TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development J. Clin. Invest. 1999 103 197 206 10.1172/JCI3523 9916131 PMC407876
8. Saito H. Inagaki Y. Tsunenari T. Ura M. Mizuno H. Fujimoto-Ouchi K. Onuma E. Sato K. Ogata E. Yamada-Okabe H. Involvement of cyclooxygenase-2 in the tumor site-dependent production of parathyroid hormone-related protein in colon 26 carcinoma Cancer Sci. 2007 98 1563 1569 10.1111/j.1349-7006.2007.00568.x 17645771 PMC11159920
9. Kir S. Komaba H. Garcia A.P. Economopoulos K.P. Liu W. Lanske B. Hodin R.A. Spiegelman B.M. PTH/PTHrP receptor mediates cachexia in models of kidney failure and cancer Cell Metab. 2016 23 315 323 10.1016/j.cmet.2015.11.003 26669699 PMC4749423
10. Hong N. Yoon H.J. Lee Y.H. Kim H.R. Lee B.W. Rhee Y. Kang E.S. Cha B.S. Lee H.C. Serum PTHrP predicts weight loss in cancer patients independent of hypercalcemia, inflammation, and tumor burden J. Clin. Endocrinol. Metab. 2016 101 1207 1214 10.1210/jc.2015-3785 26765580
11. Van Norren K. Kegler D. Argilés J.M. Luiking Y. Gorselink M. Laviano A. Arts K. Faber J. Jansen H. van der Beek E.M. Dietary supplementation with a specific combination of high protein, leucine, and fish oil improves muscle function and daily activity in tumour-bearing cachectic mice Br. J. Cancer 2009 100 713 722 10.1038/sj.bjc.6604905 19259092 PMC2653763
12. Ringbom T. Huss U. Stenholm Å. Flock S. Skattebøl L. Perera P. Bohlin L. COX-2 inhibitory effects of naturally occurring and modified fatty acids J. Nat. Prod 2001 64 745 749 10.1021/np000620d 11421736
13. Peters S.J. Van Helvoort A. Kegler D. Argilès J.M. Luiking Y.C. Laviano A. van Bergenhenegouwen J. Deutz N.E. Haagsman H.P. Gorselink M. Dose-dependent effects of leucine supplementation on preservation of muscle mass in cancer cachectic mice Oncol. Rep. 2011 26 247 254 10.3892/or.2011.1269 21503587
14. Colloton M. Shatzen E. Wiemann B. Starnes C. Scully S. Henley C. Cinacalcet attenuates hypercalcemia observed in mice bearing either Rice H-500 Leydig cell or C26-DCT colon tumors Eur. J. Pharmacol. 2013 712 8 15 10.1016/j.ejphar.2013.04.013 23623934
15. Bonetto A. Kays J.K. Parker V.A. Matthews R.R. Barreto R. Puppa M.J. Differential Bone Loss in Mouse Models of Colon Cancer Cachexia Front Physiol. 2017 7 679 10.3389/fphys.2016.00679 28123369 PMC5225588
16. Tashijan A.H. Voelkel E.F. Robinson D.R. Levine L. Dietary menhaden oil lowers plasma prostaglandins and calcium in mice bearing the prostaglandin-producing HSDM1 fibrosarcoma J. Clin. Invest 1984 74 2042 2048 10.1172/JCI111627 6439740 PMC425393
17. Orchard T. Pan X. Cheek F. A systematic review of omega-3 fatty acids and osteoporosis Br. J. Nutr. 2012 107 S253 S260 10.1017/S0007114512001638 22591899 PMC3899785
18. Hutchins-Wiese H.L. Picho K. Watkins B.A. Li Y. Tannenbaum S. Claffey K. Kenny A.M. High-Dose eicosapentaenoic acid and docosahexaenoic acid supplementation reduces bone resorption in postmenopausal breast cancer survivors on aromatase inhibitors: A pilot study Nutr. Cancer 2014 66 68 76 10.1080/01635581.2014.847964 24274259
19. Mandal C.C. Ghosh-Choudhury T. Yoneda T. Choudhury G.G. Ghosh-Choudhury N. Fish oil prevents breast cancer cell metastasis to bone Biochem Biophys Res. Commun. 2010 402 602 607 10.1016/j.bbrc.2010.10.063 20971068 PMC2993881
20. Soria B. Martin F. Cytosolic calcium oscillations and insulin release in pancreatic islets of Langerhans Diabetes Metab. 1998 24 37 40 9534007
21. Guntupalli J. Allon M. Bourke E. Effects of physiologic hyperinsulinemia on renal phosphate handling in the rat: A role for calcium Min. Electrolyte Metab. 1989 15 338 345 2693927
22. Sijben J.W.C. Calder P.C. Differential immunomodulation with long-chain n-3 PUFA in health and chronic disease Proc. Nutr. Soc. 2007 66 237 259 10.1017/S0029665107005472 17466105
23. Faber J. Berkhout M. Fiedler U. Avlar M. Witteman B.J. Vos A.P. Rapid EPA and DHA incorporation and reduced PGE2levels after one week intervention with a medical food in cancer patients receiving radiotherapy, a randomized trial Clin. Nutr. 2013 32 338 345 10.1016/j.clnu.2012.09.009 23123043
24. Faber J. Vos P. Kegler D. van Norren K. Argilés J.M. Laviano A. Beneficial immune modulatory effects of a specific nutritional combination in a murine model for cancer cachexia Br. J. Cancer 2008 99 2029 2036 10.1038/sj.bjc.6604785 19018259 PMC2607220
25. Bose M. Hao X. Ju J. Husain A. Park S. Lambert J.D. Yang C.S. Inhibition of tumorigenesis in ApcMin/+ mice by a combination of (-)-epigallocatechin-3-gallate and fish oil J. Agric. Food Chem. 2007 55 7695 7700 10.1021/jf071004r 17696481
26. Calder P.C. n − 3 Polyunsaturated fatty acids, inflammation, and inflammatory Am. J. Clin. Nutr. 2006 83 1505S 1519S 10.1093/ajcn/83.6.1505S 16841861
27. Ross J.A. Fearon K.C.H. Eicosanoid-dependent cancer cachexia and wasting Curr. Opin. Clin. Nutr. Metab. Care 2002 5 241 248 10.1097/00075197-200205000-00002 11953648
28. Trebble T. Wootton S. Miles E. Mullee M. Prostaglandin E2 production and T cell function after fishoil supplementation Am. J. Clin. Nutr. 2003 78 376 382 10.1093/ajcn/78.3.376 12936918
29. Liu Y. Chen L.Y. Sokolowska M. Eberlein M. Alsaaty S. Martinez-Anton A. Logun C. Qi H.-Y. Shelhamer J.H. The fish oil ingredient, docosahexaenoic acid, activates cytosolic phospholipase A2 via GPR120 receptor to produce prostaglandin E2 and plays an anti-inflammatory role in macrophages Immunology 2014 143 81 95 10.1111/imm.12296 24673159 PMC4137958
30. Bate C. Tayebi M. Diomede L. Salmona M. Williams A. Docosahexaenoic and eicosapentaenoic acids increase prion formation in neuronal cells BMC Biol. 2008 6 39 10.1186/1741-7007-6-39 18789130 PMC2556658
31. Strassmann G. Jacob C.O. Fong M. Bertolini D.R. Mechanisms of paraneoplastic syndromes of colon-26: Involvement of interleukin 6 in hypercalcemia Cytokine 1993 5 463 468 10.1016/1043-4666(93)90037-6 8142602
32. Prevete N. Liotti F. Amoresano A. Pucci P. de Paulis A. Melillo R.M. New perspectives in cancer: Modulation of lipid metabolism and inflammation resolution Pharmacol. Res. 2017 128 80 87 10.1016/j.phrs.2017.09.024 28986132
33. Brandão D. Ribeiro L. Dietary fatty acids modulation of human colon cancer cells: Mechanisms and future perspectives Int. J. Food Sci. Nutr. 2018 69 437 450 10.1080/09637486.2017.1382456 28984495
34. Kir S. White J.P. Kleiner S. Kazak L. Cohen P. Baracos V.E. Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia Nature 2014 1 100 104 10.1038/nature13528 25043053 PMC4224962